The first updated results in 2020 show that the addition of trastuzumab significantly improved progression-free survival and mean survival in women with advanced stage or recurrent HER2-positive cancer, with the best benefit observed in stage III or IV cancer. The gene discussed is ERBB2; the disease is cancer.